![Maria Siemionow](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Maria Siemionow founded Tolera Therapeutics, Inc. in 2007, where she worked as Chief Science Technology Officer and Dystrogen Therapeutics Corp.
in 2017, where she is working as Chief Scientific Officer from 2017.
| Unternehmen | Position | Beginn |
|---|---|---|
Dystrogen Therapeutics Corp.
 Dystrogen Therapeutics Corp. Packaged SoftwareTechnology Services Develops platform for personalized therapies for rare genetic diseases | Gründer | 01.01.2017 |
| Unternehmen | Position | Ende |
|---|---|---|
Tolera Therapeutics, Inc.
 Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel therapies and technologies for immune modulation | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 2 |
|---|---|
Tolera Therapeutics, Inc.
Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel therapies and technologies for immune modulation | Commercial Services |
Dystrogen Therapeutics Corp.
Dystrogen Therapeutics Corp. Packaged SoftwareTechnology Services Develops platform for personalized therapies for rare genetic diseases | Technology Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
